↑Ciesielski, L.; Simler, S.; Gensburger, C.; Mandel, P.; Taillandier, G.; Benoit-Guyod, J. L.; Boucherle, A.; Cohen-Addad, C. i dr.. (1979). „GABA transaminase inhibitors”. Advances in experimental medicine and biology. Advances in Experimental Medicine and Biology 123: 21–41. DOI:10.1007/978-1-4899-5199-1_2. ISBN978-1-4899-5201-1. PMID390993.edit
↑Gibson, J. P.; Yarrington, J. T.; Loudy, D. E.; Gerbig, C. G.; Hurst, G. H.; Newberne, J. W. (1990). „Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor”. Toxicologic pathology18 (2): 225–238. PMID2399411.edit
↑Polc, P.; Pieri, L.; Bonetti, E. P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. (1986). „L-cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats”. Neuropharmacology25 (4): 411–418. DOI:10.1016/0028-3908(86)90236-4. PMID3012401.edit
↑Awad, R.; Levac, D.; Cybulska, P.; Merali, Z.; Trudeau, V. L.; Arnason, J. T. (2007). „Effects of traditionally used anxiolytic botanicals on enzymes of the γ -aminobutyric acid (GABA) systemThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products”. Canadian Journal of Physiology and Pharmacology85 (9): 933–942. DOI:10.1139/Y07-083. PMID18066140.edit